Tradestie Institutional Equity Comparison Engine

CRNX vs AKRO โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-08-31 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

CRNX Overall Edge

CRNX Captures Institutional Edge (2โ€“1 Pillars ยท 3โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Crinetics Pharmaceuticals, Inc. (CRNX) driven by superior Momentum & Technical, Options & Structure while AKRO counters with relative strength in Growth & Margin. Fundamentally, CRNX trades at N/M Forward P/E with -527.4% operating margin (+2336.3% YoY revenue) versus AKRO at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, CRNX sits in UNCLASSIFIED (<1st %ile IV; Dealer Gamma Walls on Pro) against AKRO sits in UNCLASSIFIED (30th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
CRNX N/M vs AKRO N/M Fwd P/E
Growth & Margin Winner AKRO
Op Margin -527.4% vs 0.0% ยท YoY +2336.3% vs +0.0%
Momentum & Technical Winner CRNX
1Y +177.2% vs +76.8% ยท 52W Pos 100% vs 90%
Options & Structure Winner CRNX
UNCLASSIFIED (<1st %ile IV) vs UNCLASSIFIED (30th %ile IV)
CRNX NASDAQ
Crinetics Pharmaceuticals, Inc.
Pharmaceutical Preparations
$84.95
+0.13% 1D
Market Cap $9.0B
1M Return +1.71%
1Y Return +177.16%
Forward P/E N/M
Unified AI Score
46.8 / 100 HOLD
Tech 45.0 Fund 48.0 Flow 60.0 Mom 40.0
AKRO NASDAQ
Akero Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$54.65
+0.32% 1D
Market Cap $4.5B
1M Return +1.37%
1Y Return +76.75%
Forward P/E N/M
Unified AI Score
60.0 / 100 BUY
Tech 55.0 Fund 52.0 Flow 50.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: CRNX +177.16% AKRO +76.75% Spread: +38.22 pp (CRNX Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
CRNX TTM Op. Margin: -527.4% AKRO TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CRNX vs AKRO. Trailing 12-month operating profitability (CRNX -527.4% vs AKRO 0.0%) and valuation multiples (CRNX N/M vs AKRO N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: CRNX (3) vs AKRO (3)
Institutional Metric CRNX AKRO Criterion Row Winner
Market Capitalization Scale $9.0B $4.5B Larger Scale CRNX
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +2336.3% +0.0% Higher Growth CRNX
Operating Margin (TTM) Profitability -527.4% 0.0% Higher Margin AKRO
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -42.4% -34.5% Higher ROE AKRO
52-Week Range Position Momentum 100% ($30โ€“$85) 90% ($21โ€“$58) Stronger Trend CRNX
Beta / 30D Volatility Risk Regime 0.29ฮฒ ยท 2% Vol 0.90ฮฒ ยท 2% Vol Lower Realized Risk Tie
Unified Institutional Score Composite Signal 46.8 / 100 (HOLD) 60.0 / 100 (BUY) Higher Composite AKRO

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full CRNX vs AKRO Buy Guide
CRNX UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile <1st %ile
IV Regime Compressed (<25th %ile)
Live CRNX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
AKRO UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 30th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live AKRO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither CRNX nor AKRO registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.